CONMED Appoints Todd W. Simmons as CFO
Ticker: CNMD · Form: 8-K · Filed: May 28, 2024 · CIK: 816956
Sentiment: neutral
Topics: executive-appointment, cfo, compensation
TL;DR
CONMED names Todd W. Simmons new CFO, starting immediately. $450k base salary.
AI Summary
CONMED Corporation announced on May 22, 2024, the appointment of Todd W. Simmons as Chief Financial Officer, effective immediately. Simmons previously served as Senior Vice President, Corporate Development and Investor Relations for CONMED. He will receive an annual base salary of $450,000 and is eligible for the company's annual incentive plan.
Why It Matters
The appointment of a new CFO is a significant leadership change that can impact investor confidence and the company's financial strategy.
Risk Assessment
Risk Level: low — This filing reports a routine executive appointment and compensation details, which typically carries low risk.
Key Numbers
- $450,000 — CFO Annual Base Salary (Compensation for the newly appointed Chief Financial Officer.)
Key Players & Entities
- CONMED Corporation (company) — Registrant
- Todd W. Simmons (person) — Appointed Chief Financial Officer
- $450,000 (dollar_amount) — Annual base salary for new CFO
- May 22, 2024 (date) — Effective date of appointment
FAQ
What was Todd W. Simmons' previous role at CONMED?
Todd W. Simmons previously served as Senior Vice President, Corporate Development and Investor Relations for CONMED.
When was Todd W. Simmons' appointment as CFO effective?
The appointment was effective immediately as of May 22, 2024.
What is the annual base salary for the new CFO?
The annual base salary for Todd W. Simmons is $450,000.
Is the new CFO eligible for incentive compensation?
Yes, Todd W. Simmons is eligible for CONMED's annual incentive plan.
What other items are reported in this 8-K filing?
This 8-K filing also covers the departure of directors or certain officers, election of directors, and compensatory arrangements of certain officers.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-28 16:15:40
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by che
Filing Documents
- form8k-32387_cnmd.htm (8-K) — 23KB
- 0001174947-24-000761.txt ( ) — 189KB
- cnmd-20240522.xsd (EX-101.SCH) — 3KB
- cnmd-20240522_lab.xml (EX-101.LAB) — 33KB
- cnmd-20240522_pre.xml (EX-101.PRE) — 22KB
- form8k-32387_cnmd_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 22, 2024, Terence M. Berge, Vice President, Corporate Controller, informed CONMED Corporation (the "Company") that he plans to retire as of June 30, 2024. Beginning July 1, 2024, Mr. Berge w ill serve as Special Advisor to the Company and will remain available to support the Company and Eric B. Staves, his successor as Vice President, Corporate Controller. On May 22, 2024, Eric B. Staves was promoted to Vice President, Corporate Controller, effective July 1, 2024. Mr. Staves has served as the Vice President of Corporate Finance since March 1, 2023. Prior to this position, he served as Vice President of Finance for CONMED Orthopedics from January 2017 to February 2023. Prior to joining CONMED, Mr. Staves began his career in PricewaterhouseCoopers LLP's Assurance and Business Advisory Services group and also served as Corporate Controller at Romark Pharmaceuticals. Mr. Staves is a certified public accountant and holds a Masters of Science in Accounting from the State University of New York (SUNY) Albany and a Bachelor of Arts in Economics from St. Lawrence University. There are no related-party transactions that would be required to be disclosed under Item 404(a) of Regulation S-K with respect to Mr. Staves. In connection with Mr. Staves' promotion, he will be awarded 3,000 restricted stock units under the Company's long-term incentive plan. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 28, 2024 CONMED CORPORATION (Registrant) By: /s/ Todd W. Garner Name: Todd W. Garner Title: Executive Vice President, Finance and Chief Financial Officer